Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00106366 · ClinicalTrials.gov registry record · Phase 3
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 389
- Enrollment target
NCT00106366 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 389 participants.
The verdict
NCT00106366, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 389 participants
- Enrollment target
Study Summary
This trial is conducted in the United States of America (USA). The purpose of this study is to determine if the use of insulin detemir in combination with insulin aspart is safe and at least as effective as insulin glargine in combination with insulin aspart for the control of blood glucose in patients with Type 2 diabetes.
Interventions
- DRUG insulin aspart
- DRUG insulin glargine
- DRUG insulin detemir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 389 participants |
| Start Date | 2005-03 |
| Est. Completion | 2005-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00106366
The ClinicalTrials.gov registry entry for NCT00106366 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 389 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which insulin aspart is the first listed.
NCT00106366 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00106366 about?
NCT00106366 is a clinical study titled "Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes". This trial is conducted in the United States of America (USA). The purpose of this study is to determine if the use of insulin detemir in combination with insulin aspart is safe and at least as effective as insulin glargine in combination with insulin aspart for the control of blood glucose in patie...
What is the current status of trial NCT00106366?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 389 participants. The study started on 2005-03. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00106366?
The interventions under investigation include: insulin aspart (DRUG), insulin glargine (DRUG), insulin detemir (DRUG).
Who is sponsoring clinical trial NCT00106366?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.